1. Webpage: <https://jyseleca-stage.glpg.com/>

A picture containing text, grass, screenshot

Description automatically generated

JYSELECA, GALAPAGOS, and the GALAPAGOS logo are registered trademarks of Galapagos NV. © 2022 Galapagos NV. All rights reserved.GL-RA-JY-202204-00006

COMMENT: Add a space.

NOTE: This revision needs to be made on all screens where this text appears.

2. Webpage: https://jyseleca-stage.glpg.com/explore with headline **Strong RA therapy across all key clinical outcomes1,2** (frame 1)

**References: 1.** JYSELECA (filgotinib) Summary of Product Characteristics. Galapagos NV; 2022. **2.** Combe B, Kivitz A, Tanaka Y, et al. Ann Rheum Dis. 2021;80(7):848-858.

COMMENT: Set in italics.

3. Webpage: <https://jyseleca-stage.glpg.com/explore> with headline **JAK1-preferential inhibitor with a proven safety profile** (frame 2)

**References: **1.**** JYSELECA (filgotinib) Summary of Product Characteristics. Galapagos NV; 2022. ****2.**** Combe B, Kivitz A, Tanaka Y, et al. *Ann Rheum Dis.* 2021;80(7):848-858. ****3.**** Committee for Medicinal Products for Human Use (CHMP). Jyseleca Assessment Report. European Medicines Agency; 2020:1-170. ****4.**** Genovese MC, Winthrop K, Tanaka Y, et al. *Ann Rheum Dis.* 2020;79:324-325. ****5.**** Winthrop K, Tanaka Y, Takeuchi T, et al. *Arthritis Rheumatol.* 2021;73(suppl 10). ****6.**** Data on file. Galapagos NV; 2019.

COMMENT: Add a period after “2020:1-170” and then close up the line space so that “4.” runs after “2020:1-170”.

4. https://jyseleca-stage.glpg.com/explore with headline **STRENGTH OF BALANCE** (frame 4)

**References: **1.**** JYSELECA (filgotinib) Summary of Product Characteristics. Galapagos NV; 2022. ****2.**** Combe B, Kivitz A, Tanaka Y, et al. *Ann Rheum Dis*. 2021;80(7):848-858. ****3.**** Committee for Medicinal Products for Human Use (CHMP). Jyseleca Assessment Report. European Medicines Agency; 2020:1-170. ****4.**** Genovese MC, Winthrop K, Tanaka Y, et al. *Ann Rheum Dis*. 2020;79:324-325. ****5.**** Winthrop K, Tanaka Y, Takeuchi T, et al. Arthritis Rheumatol. 2021;73(suppl 10).

COMMENT: Add s: to References:

Second COMMENT: Set in italics.

5. Webpage: <https://jyseleca-stage.glpg.com/explore> (section: Resources/MOA)

a IC50 indicates how much of a specific pharmacologic agent is required to inhibit a given biological activity by half.

b Data are normalised against IFN-α.

COMMENT: Add a period for consistency with point a.

6. Webpage: <https://jyseleca-stage.glpg.com/explore> (section: Resources/MOA)

**References: **1.**** JYSELECA (filgotinib) Summary of Product Characteristics. Galapagos NV; 2022. ****2.**** Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. *Ann Rheum Dis.* 2021;80(7):865-875. ****3.**** Malemud CJ. *Int J Mol Sci.* 2017;18(3):1-9. ****4.**** Tan S, Xu J, Lai A, et al. *Mol Med Rep.* 2019;19(3):2057-2064. ****5.**** Clark JD, Flanagan ME, Telliez JB. *J Med Chem*. 2014;57(12):5023-5038. ****6.**** Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. *Nat Rev Drug Discov*. 2017;16(12):843-862. ****7.**** Virtanen AT, Haikarainen T, Raivola J, Silvennoinen O. *BioDrugs*. 2019;33(1):15-32.

COMMENT: Fix spacing by running the lines together.

9. Webpage: <https://jyseleca-stage.glpg.com/> (Galapagos Event Schedule)

Galapagos at EULAR 2022

### INDUSTRY SYMPOSIUM

**Learning objectives**

* Explore efficacy and safety goals for patients and physicians in the treatment of RA

COMMENT: Add the missing word.

10. Webpage: <https://jyseleca-stage.glpg.com/> (Study Details/Clinical Trial Programme)

### 2

Long-term extension trials 4,5  
DARWIN 3 and FINCH 4

COMMENT: Close up space.

11. Webpage: <https://jyseleca-stage.glpg.com/> (Study Details/Clinical Trial Programme)

**References: **1**.** JYSELECA (filgotinib) Summary of Product Characteristics. Galapagos NV; 2022. ****2.**** Westhovens R, Taylor PC, Alten R, et al. Ann Rheum Dis. 2017;76(6):998-1008. ****3.**** Kavanaugh A, Kremer J, Ponce L, et al. Ann Rheum Dis. 2017;76(6):1009-1019. ****4.**** Kavanaugh A, Westhovens R, Winthrop K, et al. J Rheumatol. 2021;48(8):1230-1238. ****5.**** Long term extension study to assess the safety and efficacy of filgotinib in adults with rheumatoid arthritis (FINCH 4). Clinical trials identifier: NCT03025308. Updated January 14, 2021. Accessed January 20, 2022. https://www.clinicaltrials.gov/ct2/show/NCT03025308. ****6.**** Winthrop K, Tanaka Y, Takeuchi T, et al. Arthritis Rheumatol. 2021;73(suppl 10).

COMMENT: Set in italics.